Skip to main content
FTRE logo

FTRE · Fortrea Holdings Inc.

Track FTRE — free
$20.65 +0.15 (+0.73%)
Market Cap
$1.98B
Shares
96.50M
Volume · Nov 19 257.31K Avg daily vol (3M) 1.67M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$20.50 Open$19.52 Day$19.41–20.61 52W close$8.87–25.88 Avg vol 30d1.9M Short int8.6M · 8.9% of shares · 3.7d Short vol56% Last earningsOct 29, 2026 DataJun 2023–Nov 2026 Filing10-Q · Oct 29

Up next

Feb 25, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 17
Investor event
Demand recovering across segments; Texas site acquisition closed

Fortrea CEO Anshul Thakral said demand is picking up across early-phase, biotech and biopharma work, with biotech still a growth driver. The company made a modest backlog adjustment to better reflect the rest-of-life revenue on its contracts. It also closed its Texas site acquisition, which adds a 200-bed facility.

5 source passages
Anshul Thakral, the company's CEO, for a little over a year now. we're seeing demand pick up across all three. biotech remains a growth driver in terms of percentage of growth. So we did, during the quarter, do a detailed review of our backlog positions now we have a 200-bed site readily available. Open the document at this passage
Oct 29
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Nine-month revenue falls 2.7%; backlog reduced by $558

Fortrea's revenues were $2,006.2 for the nine months ended September 30, 2026, down 2.7% from $2,062.9, and $691.5 for the quarter, down 1.4%. Backlog was $7.3 billion as of September 30, 2026, after a reduction of approximately $558 for estimated scope and study delivery changes. It also completed the acquisition of the Early Phase Services division of Worldwide Clinical Trials on October 19, 2026 for aggregate consideration of approximately $45.0.

Revenue $691.5M ▼ 1.4% Net income $600K Diluted EPS $0.01
Read from the MD&A section
5 source passages
The Company’s revenues for the nine months ended September 30, 2026 were $2,006.2, a decrease of 2.7% from revenues of $2,062.9 in the corresponding period in 2025. The Company’s revenues for the three months ended September 30, 2026 were $691.5, a decrease of 1.4% from revenues of $701.3 in the corresponding period in 2025. Our backlog was $7.3 billion as of September 30, 2026. During the quarter, in addition to ordinary course cancellations and scope reductions contracted during the period, we reduced backlog by approximately $558 to reflect the cumulative impact of estimated changes in scope and study delivery requirements across our customer contracts. On October 19, 2026, we completed the acquisition of the Early Phase Services division of Worldwide Clinical Trials for aggregate purchase consideration of approximately $45.0, Open the document at this passage
Oct 29
Earnings call
Q3 2026 earnings call

Fortrea reported third-quarter 2026 revenue of $691.5 million and adjusted EBITDA of $58.0 million, raised full-year revenue and adjusted EBITDA guidance midpoints, and expects positive free cash flow in the fourth quarter and full year.

Oct 29
Current report 8-K
Profit improves as full-year guidance rises

Fortrea reported third-quarter revenue of $691.5 million, GAAP net income of $0.6 million and adjusted EBITDA of $58.0 million for the quarter ended September 30, 2026. It raised full-year 2026 guidance and reduced backlog by $558 million.

Financial results
6 source passages
Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today reported financial results for the third quarter ended September 30, 2026. Revenue for the third quarter was $691.5 million, compared to $701.3 million in the third quarter of 2025. Third quarter GAAP net income was $0.6 million and diluted income per share was $0.01, compared to third quarter of 2025 GAAP net loss of $(15.9) million and diluted loss per share of $(0.17). Third quarter adjusted EBITDA was $58.0 million, compared to third quarter of 2025 adjusted EBITDA of $50.7 million. As a result, the Company reduced backlog by $558 million to reflect the cumulative impact of estimated scope and study delivery requirements across customer contracts, including inactive trials. The Company updated its full-year 2026 guidance, narrowing the revenue and adjusted EBITDA ranges and raising both midpoints. The Company now expects revenues of $2,665 million to $2,690 million and adjusted EBITDA of $210 million to $218 million. Open the document at this passage
Sep 30
Current report 8-K Events of Sep 29
Director or officer change, or executive pay

Fortrea Holdings Inc. appointed Carrie Russell Chief Accounting Officer effective October 5, 2026, with a $340,000 annual base salary and a 40% annual incentive bonus target.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$2.67B
Trailing 12 months
Net income (TTM)
−$68.70M
Trailing 12 months
Revenue growth YoY
-1.4%
Year over year
Operating margin
0.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
8.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$834.70M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+11.0%
Year over year · more shares
Price change (1Y)
+101.0%
Trailing year
Short interest
8.9%
Latest settlement · 3.7 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Jul 29, 2026
Q2 FY26

TL;DR. Fortrea reported Q2 2026 revenue of $678.2 million (down 4.5% YoY) and adjusted EBITDA of $58.7 million (up from $54.9M), raised full-year 2026 guidance, and booked $720.4M in net new business with a 1.06x book-to-bill, but its newly appointed CFO was placed on leave amid litigation tied to his prior employer, prompting an interim CFO appointment.

Bullish
  • + Raised full-year 2026 revenue guidance to $2.62B-$2.69B and adjusted EBITDA to $205M-$220M.
  • + Q2 book-to-bill of 1.06x with fourth consecutive quarter above 1.0x and trailing 12-month of 1.12x; first-half net new business awards up 19% YoY.
  • + Q2 adjusted EBITDA grew to $58.7M from $54.9M on cost savings and operational efficiencies.
  • + Operating cash flow improved to $28.9M (from $21.8M) and free cash flow to $19.9M (from $14.3M), with no revolver borrowings.
Bearish
  • − Q2 revenue declined 4.5% YoY to $678.2M due to lower pass-throughs and FSP headwinds.
  • − Newly appointed CFO Jason Knoblauch placed on paid leave after a Delaware court granted a TRO tied to alleged restrictive covenant violations by his prior employer.
  • − Q2 GAAP net loss of $(13.2)M with $(0.14) diluted loss per share.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +29%
above
Price vs 50-day avg −2%
below
RSI (14) 46
neutral
MACD trend Negative
52-week position 68%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −15%
trailing
6-month return +33%
trailing
YTD return +19%
this year
Relative strength +37%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $21 › 200d $16 — 50d above 200d
Institutional flow Accumulating
+3% holders QoQ · +49 funds added
Insider flow Distributing
Net -$57.2K over 90 days · 100% sells
Short interest Rising
8.88% of shares out · ▲ +11.7% MoM · 3.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
350 holders — mid 3-yr range
Squeeze score 67
elevated · 0–100
Fundamentals
Poor
Revenue growth +1%
Y/Y
EPS growth −195%
Y/Y
Balance sheet $878.2M
net debt
Quant / Vol
risk profile
Very High
Volatility 67%
annualized · 1-yr
Max drawdown −52%
past year
ATR 6.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 1 of last 3
Latest guidance · from the 8-K filed Oct 29, 2026
Revenues · full-year 2026 Raised $2.67B – $2.69B
Jul 29, 2026 $2.62B – $2.69B changed to Oct 29, 2026 $2.67B – $2.69B
prior FY $2.72B midpoint −1.7% Y/Y
Adjusted EBITDA · full-year 2026 Non-GAAP Raised $210M – $218M
Jul 29, 2026 $205M – $220M changed to Oct 29, 2026 $210M – $218M
Guided vs delivered · last 3 settled
Revenue full year 2025
guided $2.7B – $2.75B
$2.72B In line
Revenue guidance full year 2024
guided $2.7B – $2.75B
$2.7B Miss −1.0%
Revenues full year 2023
guided $3.08B – $3.13B
$2.84B Miss −8.4%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 5 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+29% Bullish
Price vs 50-day avg
−2% Neutral
RSI (14)
46 Neutral
MACD trend
Negative Bearish
52-week position
68% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $21 › 200d $16 — 50d above 200d
Institutional flow Accumulating
+3% holders QoQ · +49 funds added
Insider flow Distributing
Net -$57.2K over 90 days · 100% sells
Short interest Rising
8.88% of shares out · ▲ +11.7% MoM · 3.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
350 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $9 Now $21 · 68% Range high $26
vs 200-day avg +29% vs 50-day avg -2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
backlog 7.32B as of September 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
FTRE
Fortrea Holdings Inc.
this stock
$1.98B +18.8% +1.0% — 8.9%
VRTX
Vertex Pharmaceuticals Inc
$136.01B +18.3% +46.2% 34.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$97.81B +22.5% +20.8% 20.9 2.1%
MRNA
Moderna, Inc.
$79.63B +567.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
350
% held
106.7%
Net QoQ
+3.0M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
286
View
Short & Settlement
Short Interest Rising
Shares short
8.6M
Days to cover
3.7d
Change
+896.0K sh
View
Short Volume
Short vol %
56%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
100
Value
$2.0K
As of
Oct 9, 2026
View
Off-Exchange
Off-exchange %
50.8%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$57.2K
Buyers / Sellers
0 / 2
Buyers Sellers
View
Congressional Trades Sell
Member
James French Hill
Amount
$1.0K–$15.0K
Traded
Jun 23, 2025
View
Financials
Financials
Revenue (FY)
$2.7B
Net income (FY)
$-986.2M
EPS diluted
$-10.81
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 17, 2026
This year
18

Fortrea CEO Anshul Thakral said demand is picking up across early-phase, biotech and biopharma work, with biotech still a growth driver. The company made a modest backlog adjustment to better reflect the rest-of-life revenue on its contracts. It also closed its Texas site acquisition, which adds a 200-bed facility.

View
Proposed Sales
Value
$17.7K
Shares
1.0K
Filed
Sep 11, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 1, 2026
Last webcast
Nov 19, 2026
View
Investor Relations
Latest news
Fortrea Reports Third Quarter 202…
Published
Oct 29, 2026
Upcoming events
3
View

Performance

5D 20D 120D MTD YTD
FTRE +0.6% -14.8% +33.2% -3.7% +18.8%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY +4.5% -9.3% +36.7% -0.3% +11.8%
Key facts CIK 1965040 CUSIP 34965K107 13F (30d) 373 filings 322 filers Visit website Investor relations